Stockscreener 앱 받기
0.44%
전일 마감가:
$27.79
열려 있는:
$27.76
하루 거래량:
13.36M
Relative Volume:
0.33
시가총액:
$159.01B
수익:
$63.32B
순이익/손실:
$7.52B
주가수익비율:
21.39
EPS:
1.3043
순현금흐름:
$9.48B
1주 성능:
-3.82%
1개월 성능:
+4.30%
6개월 성능:
+4.11%
1년 성능:
+12.96%
1일 변동 폭
$27.57
$27.95
1주일 범위
$27.57
$29.21
52주 변동 폭
$23.58
$29.21
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.90 | 158.39B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,125.54 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.64 | 648.55B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.00 | 439.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.12 | 366.28B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.53 | 261.73B | 54.66B | 13.58B | 16.05B | 7.0171 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer Inc. stock slips as BMO Capital keeps positive stance and options activity spikes - AD HOC NEWS
Novartis-Pfizer trademark deal has opposite impact on their stock prices; Novartis India jumps 20% while Pfizer slips 3% - BusinessLine
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - finance.yahoo.com
Novartis India to Acquire Pfizer’s BP Drug Brands for ₹1,250 Crore - Chemical Industry Digest
Mandi Rollerson Takes on New AI Change and Adoption Leadership Role at Pfizer - hrtoday.in
Why Pfizer Stock Was so Healthy in August - finance.yahoo.com
Inside Pfizer’s Fight Against Counterfeit Medicine - Pfizer
Why Pfizer Stock Was so Healthy in August - The Motley Fool
Why Is Pfizer (NYSE:PFE) Trading At Such A Wide Discount To Its Healthcare Peers? - Kalkine Media
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - Business Wire
💊 Pfizer to discontinue Minipress XL in India 🤝 Novartis India buys the brand for ₹1,250 crore 📉 But Pfizer India gets just ₹131 crore of the deal Ekta Batra #Pfizer #Novartis #MinipressXL #PfizerIndia #NovartisIndia #CNBCTV18Digital - LinkedIn
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Novartis India acquires Pfizer brands for $132m - finance.yahoo.com
Pfizer shares hit 52-week low after Minipress XL discontinuation; Novartis zooms 13% - Business Today
Novartis India to Acquire Minipress, Minipres Trademarks From Pfizer for Rs 1,250 Crore - medicaldialogues.in
Pfizer to Discontinue Minipress XL in India, Receives USD 13.9 Mn From US Parent - medicaldialogues.in
Pfizer stock heads into the open after a flat close - AD HOC NEWS
Pfizer (PFE) Hands Broad Rights On CD228V In New Oncology Licensing Deal - simplywall.st
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now - finance.yahoo.com
Maharashtra: Novartis India buys Minipress brands from Pfizer for Rs 1250 crore - Deccan Chronicle
This Is What I'd Do With Pfizer Stock Right Now - The Globe and Mail
Novartis India to Acquire Pfizer’s Minipress Trademarks for Rs 1,250 Crore - ChemAnalyst
Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore - BusinessLine
ChrysCap-controlled Novartis India to buy Pfizer’s blood pressure brand Minipress - VCCircle
Novartis India buys Minipress brands from Pfizer for ₹1,250 crore - Business Standard
Novartis India to acquire Pfizer's 'Minipress' trademark for ₹1,250 crore - ET Manufacturing
Novartis India to Buy Pfizer’s Minipress Brand for Rs 1,250 Cr - Equitypandit
Pfizer Inc. stock gains on Minipress XL exit and solid Q2 2026 figures - AD HOC NEWS
Novartis India to acquire Minipress, Minipres Trademarks from Pfizer for Rs 1,250 crore - Business Upturn
Novartis India: Why Is the Pharma Stock Spending ₹1,250 Crore to Acquire Pfizer’s Minipress Brand? - Trade Brains
Pfizer, Inc. (PFE) Stock Analysis: Evaluating the 6.05% Dividend Yield and Its Implications for Investors - DirectorsTalk Interviews
Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Trademarks - latestly.com
Pfizer to Receive Rs 131.38 Crore After Minipress XL Discontinuation; Know Details - Dalal Street Investment Journal
Novartis India to acquire Pfizer trademarks 'Minipress' and 'Minipres' for Rs 1,250 crore - Mid-Day
Novartis India buys Minipress, Minipres rights from Pfizer for ₹1,250cr - NewsBytes
Novartis India Buys Minipress From Pfizer For ₹1,250 Crore - Whalesbook
Minipress changes hands: Novartis India buys Pfizer brands for Rs 1,250 crore - Moneycontrol.com
Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore - The Economic Times
Novartis India to acquire Pfizer's ‘Minipress’ trademark for ₹1,250 crore - BusinessLine
Pfizer to cease Minipress XL operations, secures USD 13.9 million from US parent - Business Upturn
Novartis India Acquires Pfizer's Minipress for ₹1,250 Cr - Rediff MoneyWiz
Novartis India shares jump 4% on Rs 1,250 crore Pfizer trademarks acquisition - Business Today
Novartis India Buys Minipress Brand For ₹1,250 Crore, Pfizer To Stop Selling Hypertension Drug - Free Press Journal
Pfizer to Discontinue Minipress XL, Receives $13.9M - InvestyWise
Novartis India to acquire Minipress, Pfizer’s high blood pressure drug, for ₹1,250 crore - CNBC TV18
News by CNBC TV18 on TradingView, 2026-09-07 — cnbctv:e8e1f8f6f094b:0 - TradingView
Pfizer Limited To Stop Selling Minipress XL; To Receive ₹131.38 Crore Payment - Sahi
Novartis India acquires Pfizer Minipress IP rights for ₹1,250 crore - scanx.trade
Pfizer discontinues Minipress XL sales, to receive $13.9 million - scanx.trade
Pfizer Ltd to Discontinue Minipress XL; Receives Rs 131 Crore Compensation - Whalesbook
PFE Stock Quote Price and Forecast - CNN
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
자본화:
|
볼륨(24시간):